4-(Phenylamino)pyrrolopyrimidines: Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase

Journal of Medicinal Chemistry

Volumn 39, Issue 12, 1996, Pages 2285-2292

  Traxler, Peter M ^a   Furet, Pascal ^a   Mett, Helmut ^a   Buchdunger, Elisabeth ^a   Meyer, Thomas ^a   Lydon, Nicholas ^a  

^a CIBA GEIGY LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3 BROMOPHENYL)AMINO] 5,6 DIMETHYL 7H PYRROLO [2,3 D]PYRIMIDINE; 4 [(3 BROMOPHENYL)AMINO] 5,6 TETRAMETHYLENE 7H PYRROLO[2,3 D]PYRIMIDINE; 4 [(3 CHLOROPHENYL)AMINO] 5 METHYL 6 PHENYL 7H PYRROLO[2,3 D]PYRIMIDINE; 4 [(3 CHLOROPHENYL)AMINO] 5,6 DIMETHYL 7H PYRROLO[2,3 D]PYRIMIDINE; 4 [(3 CHLOROPHENYL)AMINO] 5,6 TETRAMETHYLENE 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; NEUROKININ 3 RECEPTOR ANTAGONIST; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; COMPUTER-AIDED DESIGN; DRUG DESIGN; ENZYME INHIBITORS; GENES, FOS; GROWTH INHIBITORS; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030008414     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960118j     Document Type: Article

References (35)

1. Aaronson, S. A. Growth Factors and Cancer. Science 1991, 254, 1146-1152.
2. Hanks, S. K.; Quinn, A. M.; Hunter, T. The protein kinase family: conserved features and phylogeny of the catalytic domains. Science 1988, 241, 42-52.
3. Ullrich, A.; Schlessinger, J. Signal Transduction by Receptors with Tyrosine Kinase Activity. Cell 1990, 61, 203-212.
4. Elder, J. T.; Fisher, G. J.; Lindquist, P. B.; Bennett, G. L.; Pittelkow, M. R.; Coffey, R. J.; Ellingsworth, L.; Derynck, R; Voorhees, J. J. Overexpression of transforming growth factor α in psoriatic epidermis. Science 1989, 243, 811-814.
5. Burke, T. R. Protein-Tyrosine Kinase Inhibitors. Drugs Future 1992, 17, 119-131.
6. Fry, D. W. Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors. Exp. Opin. Invest. Drugs 1994, 3 (6), 577-595.
7. Levitzki, A.; Gazit, A. Tyrosine Kinase Inhibition: An Approach to Drug Development. Science 1995, 267, 1782-1788.
8. Traxler, P.; Lydon, N. Recent Advances in Protein Tyrosine Kinase Inhibitors, Drugs Future 1995, 20 (12), 1261-1274.
9. Spada, A. P.; Myers, M. A. Exp. Opin. Ther. Patents 1995, 5, 805-817.
10. Bridges, A. J. The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning ? Exp. Opin. Ther. Patents 1998, 5 (12), 1245-1257.
11. Geissler, J. F.; Roesel, J. L.; Meyer, T.; Trinks, U.; Traxler, P.; Lydon N. B. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. 1992, 52, 4492-4498.
12. Onoda, T.; Inuma, H.; Sasaki, Y.; Hamada, M.; Isshiki, K.; Naganawa, H.; Takeuchi, T. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J. Nat. Prod. 1989, 52 (6), 1252-1257.
13. Dolle R. E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J. E.; Baizman, E.; Harris, A. L.; Sawutz, D. G.; Miller, D.; Wan., S.; Faltynek, C. R.; Xie, W.; Sarup, J.; Bode D. C.; Pagani, E. D.; Silver, P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a Potent and Selective Inhibitor of Human Vascular P-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 1994, 37, 2627-2629.
14. Maguire, M. P.; Sheets, K. R.; McVety, K.; Spada, A. P.; Zilberstein, A. A. New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives. J. Med. Chem 1994, 372, 129-137.
15. Trinks, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, Th.; Müller, M.; Re-genass, U.; Rihs, G.; Lydon, N.; Traxler, P. Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med. Chem. 1994, 37, 1015-1027.
16. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, Th.; McGlynn, E.; Pinna, L. A.; Traxler, P.; Lydon, N. B. 4,5-Dianilinophthalimide: A protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2334-2338.
17. Buchdunger, E.; Trinks, U.; Mett, H.; Regenass, U.; Müller, M.; Meyer, Th,; Beilstein, P.; Wirz, B.; Schneider, P.; Traxler, P.; Lydon, N. B. 4,5-Bis(4-fluoro-anilino)-phthalimide: a selective inhibitor of the EGF receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res. 1995, 1, 813-821.
18. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, Th.; Müller, M.; Regenass, U.; Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2558-2562.
19. Barker, A. J.; Davies, D. H. European Patent Application (Zeneca) Nr. 0 520 722 A], December 30, 1992; Barker, A. J. European Patent Application (Zeneca) Nr. 0 566 226 A], October 20, 1993.
20. Barker, A. J.; Davies, D. H. European Patent Application (Zeneca) Nr. 0 520 722 A], December 30, 1992; Barker, A. J. European Patent Application (Zeneca) Nr. 0 566 226 A], October 20, 1993.
21. Barker, A. J.; Brown, D. S. European Patent Application (Zeneca) Nr. 602 851 A], 1993; Barker, A. J. European Patent Application (Zeneca) Nr. 635 498 A], 1994; Barker, A. J. European Patent Application (Zeneca) Nj.. 635 507 A], 1994.
22. Barker, A. J.; Brown, D. S. European Patent Application (Zeneca) Nr. 602 851 A], 1993; Barker, A. J. European Patent Application (Zeneca) Nr. 635 498 A], 1994; Barker, A. J. European Patent Application (Zeneca) Nj.. 635 507 A], 1994.
23. Barker, A. J.; Brown, D. S. European Patent Application (Zeneca) Nr. 602 851 A], 1993; Barker, A. J. European Patent Application (Zeneca) Nr. 635 498 A], 1994; Barker, A. J. European Patent Application (Zeneca) Nj.. 635 507 A], 1994.
24. Barker, A. J.; Davies, D. H.; Brown, D. S.; Woodburn, J. R.; Green, L. R.; Carlidge, S. A.; Wakeling, X. Structure activity relationships of 4-anilinoquinazolines as inhibitors of EGFR-tyrosine kinase activity. Ann. Onc. 1994, Suppl. 5, 98 (abst. 120).
25. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48 (4), 659-666.
26. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosne Kinase. Science 1994, 265, 1093-1095.
27. Myers, M. R.; Spada, A. P.; Maguire, M. P.; Persona, P. E. Patent Application (Rorer-Rhone-Poulenc) WO 9 515 758-Al, 1995.
28. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-(Phenyl-methyl-amino]-and 4-(Phenylamino)quinazolines as Potent Adenosine 5′-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. J. Med. Chem. 1995, 38 (18), 3482-3487.
29. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors. 7. 7-Amino-4-(phenylamino)-and 7-Amino-4-[(phenylmethyl)aminolpyrido[4,3-d]pyrimidines: A New Class of Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem 1995, 38, 3780-3788.
30. Furet, P.; Caravatti, G.; Priestle, J.; Sowadski, J.; Trinks, U.; Traxler, P. Modeling Study of Protein Kinase Inhibitors: Binding Mode of Staurosporine-Origin of the Selectivity of CGP 52 411. J. Comput.-Aided Mol. Des. 1995, 9, 465-472.
31. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. D.; Morgan, D. O.; Meijer, L.; Vesely, J.; Kim, S. H. Multiple Modes of Ligand Recognition: Crystal Structures of Cyclin-Dependent Protein Kinase 2 in Complex with ATP and Two Inhibitors, Olomoucine and Isopentenyladenine. Proteins: Struct., Funct., Genet. 1995, 22, 378-391.
32. Bugg, Ch. E.; Carson, W. M.; Montgomery, J. A. Drugs by Design. Sci. Am. 1993 (December), 60-66.
33. Jergensen, A.; El-Bayouki, K. A. M.; Pedersen, E. B. Phosphorous Pentoxide in Organic Synthesis. XX Synthesis of N-Aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines. J. Heterocycl. Chem. 1985, 22, 859-863.
34. Roth, H. J.; Eger, K. Synthese von 2-Amino-3-cyano-pyrrolen. Arch. Pharmaz. 1975, 308, 179-185.
35. Morgan, B. P.; Scholtz, J. M.; Ballinger, M. D.; Zipkin, I. D.; Bartlett, P. A. Differential Binding Energy: A Detailed Evaluation of the Influence of Hydrogen-Bonding and Hydrophobic Groups on the Inhibition of Thermolysin by Phosphorous-Containing Inhibitors. J. Am. Chem. Soc. 1991, 113, 297-307.